



Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference

February 5, 2025

PHILADELPHIA, Feb. 5, 2025 /PRNewswire/ -- [Carisma Therapeutics Inc.](#) (Nasdaq: [CARM](#)) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced that Steven Kelly, President and Chief Executive Officer, will participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11 at 4:40 pm ET.

—
An audio webcast of the event will be available on the Company's [Investor Events](#) section of the Investor Relations webpage and will be archived for a limited time following the event.

About Carisma

Carisma Therapeutics is a biopharmaceutical Company pioneering macrophage engineering to develop groundbreaking therapies for fibrosis, cancer, and other diseases. With a strong commitment to patient-centric innovation, Carisma aims to deliver scalable, next-generation solutions that transform treatment paradigms. Carisma is headquartered in Philadelphia, PA. For more information, please visit www.Carimatx.com.

Investors:

Shveta Dighe

investors@carimatx.com

Media Contact:

Julia Stern

(763) 350-5223

jstern@realchemistry.com

 View original content to download multimedia: <https://www.prnewswire.com/news-releases/carisma-therapeutics-to-participate-in-oppenheimer-35th-annual-healthcare-life-sciences-conference-302367990.html>

SOURCE Carisma Therapeutics Inc.